全文获取类型
收费全文 | 41622篇 |
免费 | 3225篇 |
国内免费 | 129篇 |
专业分类
耳鼻咽喉 | 407篇 |
儿科学 | 1238篇 |
妇产科学 | 1041篇 |
基础医学 | 6142篇 |
口腔科学 | 659篇 |
临床医学 | 5790篇 |
内科学 | 7579篇 |
皮肤病学 | 787篇 |
神经病学 | 4256篇 |
特种医学 | 1045篇 |
外科学 | 4123篇 |
综合类 | 449篇 |
现状与发展 | 1篇 |
一般理论 | 33篇 |
预防医学 | 4167篇 |
眼科学 | 700篇 |
药学 | 2857篇 |
中国医学 | 57篇 |
肿瘤学 | 3645篇 |
出版年
2023年 | 283篇 |
2022年 | 479篇 |
2021年 | 1036篇 |
2020年 | 671篇 |
2019年 | 1045篇 |
2018年 | 1248篇 |
2017年 | 953篇 |
2016年 | 1057篇 |
2015年 | 1096篇 |
2014年 | 1566篇 |
2013年 | 2059篇 |
2012年 | 3213篇 |
2011年 | 3289篇 |
2010年 | 1801篇 |
2009年 | 1615篇 |
2008年 | 2791篇 |
2007年 | 2916篇 |
2006年 | 2648篇 |
2005年 | 2707篇 |
2004年 | 2427篇 |
2003年 | 2280篇 |
2002年 | 2121篇 |
2001年 | 509篇 |
2000年 | 376篇 |
1999年 | 475篇 |
1998年 | 473篇 |
1997年 | 382篇 |
1996年 | 302篇 |
1995年 | 292篇 |
1994年 | 236篇 |
1993年 | 222篇 |
1992年 | 241篇 |
1991年 | 192篇 |
1990年 | 196篇 |
1989年 | 192篇 |
1988年 | 164篇 |
1987年 | 142篇 |
1986年 | 123篇 |
1985年 | 111篇 |
1984年 | 114篇 |
1983年 | 101篇 |
1982年 | 84篇 |
1981年 | 94篇 |
1980年 | 87篇 |
1979年 | 69篇 |
1978年 | 58篇 |
1977年 | 58篇 |
1976年 | 44篇 |
1975年 | 39篇 |
1974年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
ABSTRACTIn clinical trials, selection of appropriate study endpoints is critical for an accurate and reliable evaluation of safety and effectiveness of a test treatment under investigation. In practice, however, there are usually multiple endpoints available for measurement of disease status and/or therapeutic effect of the test treatment under study. For example, in cancer clinical trials, overall survival, response rate, and/or time to disease progression are usually considered as primary clinical endpoints for evaluation of safety and effectiveness of the test treatment under investigation. Once the study endpoints have been selected, sample size required for achieving a desired power is then determined. It, however, should be noted that different study endpoints may result in different sample sizes. In practice, it is usually not clear which study endpoint can best inform the disease status and measure the treatment effect. Moreover, different study endpoints may not translate one another although they may be highly correlated one another. In this article, we intend to develop an innovative endpoint namely therapeutic index based on a utility function to combine and utilize information collected from all study endpoints. Statistical properties and performances of the proposed therapeutic index are evaluated theoretically. A numerical example concerning a cancer clinical trial is given to illustrate the use of the proposed therapeutic index. 相似文献
4.
5.
6.
Jeffrey Buenaflor Parker Sommerville Hang Qian Christine Luscombe 《Macromolecular chemistry and physics.》2020,221(2)
A comparative study involving bimetallic nickel catalysts designed from disubstituted N,N,N′,N′‐tetra(diphenylphosphanylmethyl)benzene diamine bridging ligands is reported. Catalyst behavior is explored in the Kumada catalyst‐transfer polymerization (KCTP) using poly(3‐hexylthiophene) (P3HT) as the model system. The success of a controlled polymerization is monitored by analyzing monomer conversion, degree of polymerization, end‐group identity, and molecular weight distribution. The characterization of P3HT obtained from KCTP initiated with the bimetallic catalysts shows chain‐growth behavior; however, the presence of Br/Br end‐groups and broader molecular weight distribution reveals a reduced controlled polymerization compared to the commonly employed Ni(dppp)Cl2. The observed increase in intermolecular chain transfer and termination processes in KCTP initiation with the bimetallic catalysts can be attributed to a weaker Ni(0)‐π‐aryl complex interaction, which is caused by increased steric crowding of the coordination sphere. 相似文献
7.
8.
9.
10.
Ngai-Yin Chan Chi-Chung Choy Ho-Chuen Yuen Hoi-Fan Chow Ho-Fai Fong 《The Canadian journal of cardiology》2019,35(4):396-404